Andrew Rubin, MD
Clinical Cardiac Electrophysiology · Rancho Mirage, CANPI 1629038021
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Abbott at 36.3% of the total. Reporting peaked in 2019 at $69,281 and has fallen 98.0% since, to $1,392 in 2025.
Across 564 payments — averaging $246.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$50K
- Johnson & Johnson$44K
- E.r. Squibb & Sons, L.L.C.$15K
- AstraZeneca$9K
- Pfizer$6K
- Medtronic$6K
- plus $9K from 18 others
Across 143 payments — averaging $2966.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$375K
- Medtronic$42K
- Boston Scientific$8K
What the payments were for
- Consulting fees$49,29636%
- Speaking & faculty fees$71,00851%
- Travel & lodging$3,9903%
- Food & beverage$14,55810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 101 | $50,365 |
| Johnson & Johnson | 63 | $43,829 |
| E.r. Squibb & Sons, L.L.C. | 27 | $14,931 |
| AstraZeneca(2 entities) | 13 | $9,120 |
| Pfizer | 10 | $6,081 |
| Medtronic(2 entities) | 128 | $5,657 |
| Boston Scientific | 197 | $5,210 |
| Portola Pharmaceuticals, LLC | 1 | $2,250 |
| Atricure, Inc. | 5 | $365 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $160 |
| Abiomed | 1 | $157 |
| Impulse Dynamics (USA) Inc. | 2 | $113 |
| Acutus Medical, Inc. | 1 | $105 |
| Edwards Lifesciences | 1 | $94 |
| Cardiofocus, Inc. | 1 | $89 |
| Siemens Medical Solutions USA, Inc. | 1 | $76 |
| Baxter Healthcare | 1 | $51 |
| Novartis | 2 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Philips North America LLC | 2 | $35 |
| Amgen | 1 | $28 |
| Endotronix, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Elutia, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$43,008
- Allure Quadra RF CRT Pacemaker$28,547
- ELIQUIS$19,013
- ANDEXXA$11,142
- Confirm Rx$8,096
- Quadra Allure MP RF CRT Pacemkr$6,254
- Micra$3,610
- Allure CRT Pacemaker$3,459
- Fortify Assura, Ellipse ICD$1,440
- Assurity Pacemaker$366
- Impella$157
- WATCHMAN FLX$134
- LifeVest$133
- Ensite Cardiac Mapping System$131
- RELIANCE 4 FRONT$106
- GENERAL BRADY$100
How this compares
$138,851 in reported general payments places this provider in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 757 | $892,257 |
| XareltoRivaroxaban | 323 | $405,994 |
| JardianceEmpagliflozin | 189 | $246,987 |
| EntrestoSacubitril/Valsartan | 87 | $120,626 |
| FarxigaDapagliflozin Propanediol | 37 | $45,402 |
| MultaqDronedarone Hcl | 15 | $25,176 |
| Repatha SureclickEvolocumab | 18 | $23,257 |
| Flecainide Acetate | 500 | $21,058 |
| Praluent PenAlirocumab | 12 | $10,851 |
| VascepaIcosapent Ethyl | 17 | $10,452 |
| Nebivolol Hcl | 107 | $8,354 |
| Atorvastatin Calcium | 748 | $8,175 |
| Metoprolol Succinate | 532 | $7,603 |
| PradaxaDabigatran Etexilate Mesylate | 20 | $7,038 |
| Ezetimibe | 184 | $6,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,081 | $892,257757 claims |
| Johnson & JohnsonXarelto | $43,829 | $405,994323 claims |
| NovartisEntresto | $40 | $120,62687 claims |
| AstraZenecaFarxiga | $9,120 | $45,40237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Rancho Mirage
- Leon FeldmanRancho Mirage$303K
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
- Rajesh BankerNewport Beach$538K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.